Nabriva Therapeutics PLCOver The Counter Market:NBRVF
- LAST PRICE0.0002
- TODAY'S CHANGE (%)-0.0001 (-33.3333%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0002 / 0.0003
- Day Range
- 52 Week Range
- Volume762
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NBRVF |
|---|---|---|
| 12:37 ET | 430 | 0.0002 |
| 01:54 ET | 160 | 0.0002 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Nabriva Therapeutics PLC | 970.0 | 0.0x | --- |
Equillium Inc | 26.6M | -3.1x | --- |
Emmaus Life Sciences Inc | 1.7M | -0.6x | --- |
Pieris Pharmaceuticals Inc | 22.4M | -0.9x | --- |
Predictive Technology Group Inc | 59.9K | 0.0x | --- |
RVL Pharmaceuticals PLC | 110.0 | 0.0x | --- |
Company Information
Nabriva Therapeutics PLC is a biopharmaceutical company. The Company is engaged in the commercialization and development of anti-infective agents to treat serious infections. The Company's product is XENLETA (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP). XENLETA is designed to inhibit the synthesis of a specific protein on the bacterial ribosome, which is required for bacteria to grow, by binding with high affinity and specificity at molecular targets that are different than other available antibiotic classes causing cell death.
Contact Information
- Headquarters
- Alexandra House Office 225/227 , The Sweepstakes,, BallsbridgeDUBLIN, Ireland D01 H104
- Phone
- 610-816-6640
- Fax
- ---
Executives
- Independent Chairman of the Board
- Daniel Burgess
- Chief Executive Officer
- H. Michael Hogan
- Chief Financial Officer
- Dave Maggio
- Chief Medical Officer
- Christine Guico-Pabia
- Director
- Steven Gelone
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $970.00 |
|---|---|
Revenue (TTM) | $29.6M |
Shares Outstanding | 3.2M |
Nabriva Therapeutics PLC does not pay a dividend. | |
Beta | -7.60 |
EPS | $-17.99 |
Book Value | $1.03 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 0.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -182.81% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
